TowardsBuddha Corp. announces a major investment in expanding its Taiwan-based production capacity to strengthen rapid prototyping and small-batch manufacturing of medical-grade TPU catheters. The expansion aims to respond to growing domestic and international demand for high-quality, traceable medical devices while adding agility to the company’s global supply chain footprint.

Key aspects of the investment include upgrading extrusion and molding equipment to improve product consistency, establishing dedicated clean inspection zones to enhance cleanliness control, and implementing a comprehensive material traceability system to ensure each lot meets international standards such as USP Class VI and ISO 10993. The company has also reinforced its rapid-prototyping team to shorten the cycle from design sample to clinical evaluation, enabling faster response to clinical needs.

Facing an increasingly focused global market that demands safety, sustainability, and clinically friendly materials, enhancing local capacity and quality assurance is seen as essential for strengthening brand trust and accelerating international partnerships. With this upgrade, TowardsBuddha will expand its range of customization options — including radiopaque lines, TPU grade selection, optional barium sulfate, and color coding — while offering improved delivery times and stricter quality control for healthcare supply chains.

Looking ahead, the company plans to continue investing in R&D and collaborate with clinical design consultants to advance clinically oriented product improvements. TowardsBuddha emphasizes that environmental and energy-efficiency measures will be integrated during the expansion to align with its long-term vision of promoting green healthcare materials.